Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report-Reference-Cited by-同舟云学术

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

Published:2021-10-13 Issue:23 Volume:12 Page:3273-3276
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Li Shuluan¹^ORCID,Zhang Pei²,Wang Tianyu³^ORCID,Wang Jie²^ORCID,Duan Jianchun²

Affiliation:

1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China

2. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

3. Department of Breast Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14133

Reference20 articles.

1. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare

2. ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung

3. Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

4. First‐line crizotinib in ALK‐positive lung cancer;Solomon BJ;N Engl J Med,2015

5. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Anaplastic Lymphoma Kinase-rearranged Squamous Cell Lung Cancer Treated with Sequential ALK-tyrosine Kinase Inhibitor Therapy: a Case Report;Haigan;2022-12-20

2. Carboplatin/gemcitabine;Reactions Weekly;2022-05